Recently Featured

Class 3 Medicines Recall: Flamingo Pharma UK Ltd, Flucloxacillin Capsules BP 500mg, EL(26)A/32

July 20, 2026
Flamingo Pharma UK Ltd has issued a Class 3 medicines recall for specific packs of Flucloxacillin Capsules BP 500mg due to a packaging error. The affected packs inadvertently contain the Patient Information Leaflet (PIL) for Amoxicillin 500mg Capsules instead of the correct PIL for Flucloxacillin. This mislabeling poses a significant risk of patient confusion and…

Relonchem Limited Issues Class 4 Medicines Defect Notification for Gabapentin Oral Solution

July 20, 2026
Relonchem Limited has notified the Medicines and Healthcare products Regulatory Agency (MHRA) of a Class 4 Medicines Defect concerning its Gabapentin Relonchem 50mg/ml Oral Solution. This notification follows reports of particulate matter observed in some bottles, which were identified through a customer complaint. The presence of particles in a medicinal product raises significant safety concerns,…

After Monotherapy Failure, AbbVie and Genmab Tout Epkinly Combo Win in DLBCL

July 20, 2026
Despite a recent setback as a second-line monotherapy in diffuse large B-cell lymphoma (DLBCL), AbbVie and Genmab are celebrating a successful phase 3 combination trial for their drug Epkinly. This positive outcome comes at a crucial time, as it sets the stage for an upcoming high-stakes readout in the first-line treatment setting. The trial results…

FDA selects Lilly, Regeneron, Fujifilm, 4 others for PreCheck Pilot Program

July 20, 2026
Eli Lilly, Regeneron, and Fujifilm are among the seven companies selected for the FDA’s PreCheck Pilot Program, aimed at enhancing drug manufacturing and supply chain resilience in the United States. The initiative includes participation from Amneal, Cellares, Kriya, and Kyowa Kirin, reflecting a diverse group of stakeholders in the pharmaceutical landscape. This program is a…

Ongoing Cases